CoChat

Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer

Open access
Yang, James Chih-Hsin, Lee, Dae Ho, Lee, Jong-Seok, Fan, Yun, de Marinis, Filippo, Iwama, Eiji, Inoue, Takako, Rodríguez-Cid, Jerónimo, Zhang, Li, Yang, Cheng-Ta, de la Mora Jimenez, Emmanuel, Zhou, Jianying, Pérol, Maurice, Lee, Ki Hyeong, Vicente, David, Ichihara, Eiki, Riely, Gregory J., Luo, Yiwen, Chirovsky, Diana, Pietanza, M. Catherine, Bhagwati, Niyati, Lu, Shun, Joseph Boyer, Michael, Hui, Rina, Wong, Mark, Mant, Andrew, Parente, Phillip, John, Thomas, Parakh, Sagun, Castro, Gilberto, Werutsky, Gustavo, de Azevedo, Sergio Jobim, Andre Franke, Fabio, De Almeida Rego, Joilda Batista, Martins De Marchi, Pedro Rafael, Dix Junqueira, Gustavo, Maris Peria, Fernanda, Brust, Leandro, Cheema, Parneet, Doherty, Mark, Parmar, Ambika, Menjak, Ines B., Leighl, Natasha B., Agulnik, Jason, Lu, Shun, Han, Zhigang, Cui, Jiuwei, Zhang, Li, Cheng, Ying, Chen, Gongyan, Zhang, Helong, Yao, Yu, Hu, Chengping, Wang, Qiming, Zhang, Xin, Zhang, Yong, Zhou, Jianying, Ying, Kejing, Fan, Yun, Wang, Yan, Wang, Ziping, Feng, Jifeng, Du, YingYing, Wu, Lin, Huang, Cheng, Zhou, Xiangdong, Perol, Maurice, Domont, Julien, Lamour, Corinne, Dutilh, Julien, Oulkhouir, Youssef, Westeel, Virginie, Carmier, Delphine, Coudert, Bruno, Lagrange, Aurelie, Spaeth, Dominique, Ropert, Stanislas, Christoph, Daniel C., Kern, Jens, Kopp, Hans-Georg, Griesinger, Frank, Wiewrodt, Rainer, Wermke, Martin, Wesseler, Claas, Mueller, Annette, Vogel, Gunther, Lee, Victor, James Ho, Chung Man, Oscar Chan, Siu Hong, Hung Lo, Sing, Jonathan Nyaw, Shi Feng, Jacky Li, Yu Chung, Bar, Jair, Gottfried, Maya, Dudnik, Julia, Zer, Alona, Moskovitz, Mor, Wollner, Mirjana, Rotem, Ofer, Shamai, Sivan, Asna, Noam, Kamel, Mhameed, Novello, Silvia, Di Costanzo, Francesco, Doni, Laura, Mazzoni, Francesca, Ferrau, Francesco, de Marinis, Filippo, Tonini, Giuseppe, Galetta, Domenico, Piantedosi, Francovito, Vitiello, Fabiana, Kirita, Keisuke, Yoh, Kiyotaka, Takahashi, Toshiaki, Ohe, Yuichiro, Hattori, Yoshihiro, Okamoto, Isamu, Kurata, Takayasu, Yoshioka, Hiroshige, Saka, Hideo, Oki, Masahide, Kato, Terufumi, Tanaka, Hiroshi, Kumagai, Toru, Inoue, Takako, Hida, Toyoaki, Horio, Yoshitsugu, Teraoka, Shunsuke, Ichihara, Eiki, Kishi, Kazuma, Takaya, Hisashi, Takai, Daiya, Kozuki, Toshiyuki, Kasahara, Kazuo, Tambo, Yuichi, Hosomi, Yukio, Kondo, Masashi, Ichiki, Masao, Takeoka, Hiroaki, de la Mora Jimenez, Emmanuel, Hernandez, Carlos Alberto, Rodriguez Cid, Jeronimo Rafael, Rodriguez, Oscar Gerardo Arrieta, Han, Ji-Youn, Min, Young Joo, Kim, Dong-Wan, Park, Keunchil, Lee, Se-Hoon, Lee, Ki Hyeong, Lee, Jong-Seok, Kang, Jin Hyoung, Lee, Dae Ho, Cho, Eun Kyung, Carcereny, Enric, Lopez, Pilar Garrido, Tarruella, Margarita Majem, Rodriguez, Luis Paz-Ares, Vicente Baz, David, Font, Enriqueta Felip, Cobo-Dols, Manuel, Ekman, Simon, Bergman, Bengt, Ohman, Ronny, Vikstrom, Anders, Yang, Chih-Hsin, Chiu, Chao-Hua, Huang, Hsu-Ching, Yang, Cheng-Ta, Su, Jian, Chang, Gee-Chen, Yang, Tsung-Ying, Hsia, Te-Chun, Su, Wu-Chou, Wu, Shang-Yin, Wang, Chin-Chou, Lee, Kang-Yun, Lin, Sheng-Hao, Lin, Chih-Bin, Lee, Jih-Hsiang, Huang, Chun-Yao, Ahmed, Samreen, Newsom-Davis, Thomas, Baijal, Shobhit, Brock, Juliet, Zaki, Kam, Shamash, Jonathan, Papadatos-Pastos, Dionysis, Jain, Pooja, Jane Mackean, Melanie, Kendall, Stephan DiSean, Anderson, Ian, Costin, Dan, Hall, Richard, Campbell, Nicholas, Khan, Saad, Dowell, Jonathan, Mashru, Sandeep, Menon, Smitha, Raza, Ahmad, Ge, Li, Riely, Gregory J., Seetharamu, Nagashree, Stampleman, Laura, Subramanian, Janakiraman, Wender, Donald B., Natale, Ronald B., Zhu, Viola, Ignatius Ou, Sai-Hong, Sanborn, Rachel, Evangelist, Makenzi C. · 2024 · Journal of Clinical Oncology
Cited by 165

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

PURPOSE: Epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitors (TKIs) are standard first-line therapy for EGFR -mutant, metastatic non–small cell lung cancer (NSCLC); however, most patients experience disease progression. We report results from the randomized, double-blind, phase III KEYNOTE-789 study of pemetrexed and platinum–based chemotherapy with or without pembrolizumab for TKI-resistant, EGFR -mutant, metastatic nonsquamous NSCLC (ClinicalTrials.gov identifier: NCT03515837 ). METHODS: Adults with pathologically confirmed stage IV nonsquamous NSCLC, documented DEL19 or L858R EGFR mutation, and progression after EGFR-TKI treatment were randomly assigned 1:1 to 35 cycles of pembrolizumab 200 mg or placebo once every 3 weeks plus four cycles of pemetrexed and carboplatin or cisplatin once every 3 weeks and then maintenance pemetrexed. Dual primary end points were progression-free survival (PFS) and overall survival (OS). Final PFS testing was completed at the second interim analysis (IA2; data cutoff, December 3, 2021); OS was tested at final analysis (FA; data cutoff, January 17, 2023). Efficacy boundaries were one-sided P = .0117 for PFS and OS. RESULTS: Four hundred ninety-two patients were randomly assigned to pembrolizumab plus chemotherapy (n = 245) or placebo plus chemotherapy (n = 247). At IA2, the median PFS was 5.6 months for pembrolizumab plus chemotherapy versus 5.5 months for placebo plus chemotherapy (hazard ratio [HR], 0.80 [95% CI, 0.65 to 0.97]; P = .0122). At FA, the median OS was 15.9 versus 14.7 months, respectively (HR, 0.84 [95% CI, 0.69 to 1.02]; P = .0362). Grade ≥3 treatment-related adverse events occurred in 43.7% of pembrolizumab plus chemotherapy recipients versus 38.6% of placebo plus chemotherapy recipients. CONCLUSION: Addition of pembrolizumab to chemotherapy in patients with TKI-resistant, EGFR -mutant, metastatic nonsquamous NSCLC did not significantly prolong PFS or OS versus placebo plus chemotherapy in KEYNOTE-789.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.23.02747

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 165

Metadata

Authors
Yang, J. C.-H., Lee, D. H., Lee, J.-S., Fan, Y., de Marinis, F., Iwama, E., Inoue, T., Rodríguez-Cid, J., Zhang, L., Yang, C.-T., de la Mora Jimenez, E., Zhou, J., Pérol, M., Lee, K. H., Vicente, D., Ichihara, E., Riely, G. J., Luo, Y., Chirovsky, D., Pietanza, M. C., Bhagwati, N., Lu, S., Joseph Boyer, M., Hui, R., Wong, M., Mant, A., Parente, P., John, T., Parakh, S., Castro, G., Werutsky, G., de Azevedo, S. J., Andre Franke, F., De Almeida Rego, J. B., Martins De Marchi, P. R., Dix Junqueira, G., Maris Peria, F., Brust, L., Cheema, P., Doherty, M., Parmar, A., Menjak, I. B., Leighl, N. B., Agulnik, J., Lu, S., Han, Z., Cui, J., Zhang, L., Cheng, Y., Chen, G., Zhang, H., Yao, Y., Hu, C., Wang, Q., Zhang, X., Zhang, Y., Zhou, J., Ying, K., Fan, Y., Wang, Y., Wang, Z., Feng, J., Du, Y., Wu, L., Huang, C., Zhou, X., Perol, M., Domont, J., Lamour, C., Dutilh, J., Oulkhouir, Y., Westeel, V., Carmier, D., Coudert, B., Lagrange, A., Spaeth, D., Ropert, S., Christoph, D. C., Kern, J., Kopp, H.-G., Griesinger, F., Wiewrodt, R., Wermke, M., Wesseler, C., Mueller, A., Vogel, G., Lee, V., James Ho, C. M., Oscar Chan, S. H., Hung Lo, S., Jonathan Nyaw, S. F., Jacky Li, Y. C., Bar, J., Gottfried, M., Dudnik, J., Zer, A., Moskovitz, M., Wollner, M., Rotem, O., Shamai, S., Asna, N., Kamel, M., Novello, S., Di Costanzo, F., Doni, L., Mazzoni, F., Ferrau, F., de Marinis, F., Tonini, G., Galetta, D., Piantedosi, F., Vitiello, F., Kirita, K., Yoh, K., Takahashi, T., Ohe, Y., Hattori, Y., Okamoto, I., Kurata, T., Yoshioka, H., Saka, H., Oki, M., Kato, T., Tanaka, H., Kumagai, T., Inoue, T., Hida, T., Horio, Y., Teraoka, S., Ichihara, E., Kishi, K., Takaya, H., Takai, D., Kozuki, T., Kasahara, K., Tambo, Y., Hosomi, Y., Kondo, M., Ichiki, M., Takeoka, H., de la Mora Jimenez, E., Hernandez, C. A., Rodriguez Cid, J. R., Rodriguez, O. G. A., Han, J.-Y., Min, Y. J., Kim, D.-W., Park, K., Lee, S.-H., Lee, K. H., Lee, J.-S., Kang, J. H., Lee, D. H., Cho, E. K., Carcereny, E., Lopez, P. G., Tarruella, M. M., Rodriguez, L. P.-A., Vicente Baz, D., Font, E. F., Cobo-Dols, M., Ekman, S., Bergman, B., Ohman, R., Vikstrom, A., Yang, C.-H., Chiu, C.-H., Huang, H.-C., Yang, C.-T., Su, J., Chang, G.-C., Yang, T.-Y., Hsia, T.-C., Su, W.-C., Wu, S.-Y., Wang, C.-C., Lee, K.-Y., Lin, S.-H., Lin, C.-B., Lee, J.-H., Huang, C.-Y., Ahmed, S., Newsom-Davis, T., Baijal, S., Brock, J., Zaki, K., Shamash, J., Papadatos-Pastos, D., Jain, P., Jane Mackean, M., Kendall, S. D., Anderson, I., Costin, D., Hall, R., Campbell, N., Khan, S., Dowell, J., Mashru, S., Menon, S., Raza, A., Ge, L., Riely, G. J., Seetharamu, N., Stampleman, L., Subramanian, J., Wender, D. B., Natale, R. B., Zhu, V., Ignatius Ou, S.-H., Sanborn, R., & Evangelist, M. C.
Venue
Journal of Clinical Oncology
Published
2024-12
Volume
42
Issue
34
Pages
4029-4039
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W4401742667
Cited by
165
References
7
FWCI
40.57
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.